Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C

N/AUnknownNCT01900886

Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria263 enrolled

Overview

Primary objective: Evaluate the prevalence of personality disorders in patients starting treatment for hepatitis C in the prison and determine their influence on the evolution of the disease.

Secondary objectives: * Describe the management of patients with personality disorders on treatment for hepatitis C in the prison. * Describe the characteristics of patients who discontinue the treatment and the reasons for stratifying by the presence of personality disorders.

Study Type

OBSERVATIONAL

Enrollment

263

Conditions

Hepatitis C, Chronic Personality Disorders in Prison

Interventions

Peginterferon alfa-2aOTHER

Treatment as usual clinical practice

RibavirinDRUG

Treatment as usual clinical practice

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 years of age. * Patients with expected prison stay beyond the duration of follow-up period of the study. * Patients with chronic HCV infection and detectable viral load to initiate treatment with standard therapy. * Patients their written informed consent to participate in the study. Exclusion Criteria: * Patients previously treated with Interferon (IFN) and Ribavirin (RBV). * Patients can not read or understand a written questionnaire at the discretion of the investigator.

Locations (11)

Centro Penitenciario de El Acebuche

Almería, Almeria, Spain

Centro Penitenciario de Badajoz

Badajoz, Badajoz, Spain

Centro Penitenciario El Puerto III

Jerez de la Frontera, Cadiz, Spain

Outcomes

Primary Outcomes

Sustained Viral Response (SVR)

Time frame: RNA-VHC at weeks 24 or 48

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.